LH

SEC source: 0001127602-22-024923 · form4.xml · derivative · entry 5

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,844

Underlying: Common Stock · 12,032 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F7 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vested in three installments as follows: 30% of the Restricted Stock Units vested on November 1, 2020; 30% of the Restricted Stock Units vested on November 1, 2021; and 40% of the Restricted Stock Units vested on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that could have adjusted the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR but ultimately did not result in an adjustment.

F7 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vested in three installments as follows: 30% of the Restricted Stock Units vested on November 1, 2020; 30% of the Restricted Stock Units vested on November 1, 2021; and 40% of the Restricted Stock Units vested on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that could have adjusted the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR but ultimately did not result in an adjustment.

F8 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-22-024923 · form4.xml · derivative · entry 4

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,876

Underlying: Common Stock · 9,170 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F6 · derivative.exercise_date: The Restricted Stock Units vest in full on April 15, 2024.

F6 · derivative.expiration_date: The Restricted Stock Units vest in full on April 15, 2024.

SEC source: 0001127602-22-024923 · form4.xml · derivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,170

Underlying: Common Stock · 9,170 shares

Expires 2024-05-10

F3 · security: Performance Share Unit granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

F4 · derivative.exercise_price: Each Performance Share Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F5 · derivative.exercise_date: The Performance Share Units vest in full upon the filing of the Company's Quarterly Report on Form 10-Q for the first quarter of 2024, subject to both continued service and a performance condition related to the Issuer's contemplated spin-off transaction.

F5 · derivative.expiration_date: The Performance Share Units vest in full upon the filing of the Company's Quarterly Report on Form 10-Q for the first quarter of 2024, subject to both continued service and a performance condition related to the Issuer's contemplated spin-off transaction.

SEC source: 0001127602-22-024923 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,842

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-024923 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,190

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-22-024922 · form4.xml · derivative · entry 3

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,024

Underlying: Common Stock · 2,007 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested.

F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-22-024922 · form4.xml · nonDerivative · entry 2

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,588

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-024922 · form4.xml · nonDerivative · entry 1

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-22-024921 · form4.xml · derivative · entry 3

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,897

Underlying: Common Stock · 2,007 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested.

F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-22-024921 · form4.xml · nonDerivative · entry 2

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,030

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-024921 · form4.xml · nonDerivative · entry 1

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,922

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-22-023933 · form4.xml · derivative · entry 1

Kliphouse Kirsten Marie · CIK 0001948684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333

Underlying: Common Stock · 333 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units vest fully on October 12, 2023.

F2 · derivative.expiration_date: The Restricted Stock Units vest fully on October 12, 2023.

SEC source: 0001127602-22-023065 · form4.xml · nonDerivative · entry 4

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,158

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

F5 · price: The price of $211.8634 per share represents a weighted average of sales prices ranging from $211.66 to $212.13 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-22-023065 · form4.xml · nonDerivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,988

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

F4 · price: The price of $211.1346 per share represents a weighted average of sales prices ranging from $210.66 to $211.65 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-22-023065 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,687

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price of $210.2068 per share represents a weighted average of sales prices ranging from $209.66 to $210.64 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-22-023065 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,531

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price of $209.2940 per share represents a weighted average of sales prices ranging from $208.65 to $209.62 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-22-022354 · form4.xml · nonDerivative · entry 1

Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,281.78

F1 · balance_after: Amount includes 65.5254 shares acquired on June 30, 2022 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan.

SEC source: 0001127602-22-020514 · form4.xml · derivative · entry 9

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,600 shares

Expires 2029-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

F5 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column.

SEC source: 0001127602-22-020514 · form4.xml · derivative · entry 8

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,100 shares

Expires 2028-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

F5 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column.

SEC source: 0001127602-22-020514 · form4.xml · derivative · entry 7

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,400 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

F5 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column.

SEC source: 0001127602-22-020514 · form4.xml · nonDerivative · entry 6

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,158

F3 · price: The price of $254.879 per share represents a weighted average of sales prices ranging from $254.75 to $255.02 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-22-020514 · form4.xml · nonDerivative · entry 5

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,658

F2 · price: The price of $254.259 per share represents a weighted average of sales prices ranging from $253.71 to $254.71 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-22-020514 · form4.xml · nonDerivative · entry 4

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,996

F1 · price: The price of $253.265 per share represents a weighted average of sales prices ranging from $252.71 to $253.70 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-22-020514 · form4.xml · nonDerivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-020514 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,658

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-020514 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-020320 · form4.xml · derivative · entry 8

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 764

Underlying: Common Stock · 50 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on August 1, 2021.

F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on August 1, 2021.

F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-22-020320 · form4.xml · derivative · entry 7

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 767 shares

Expires 2029-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

F4 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column.

SEC source: 0001127602-22-020320 · form4.xml · nonDerivative · entry 6

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,914.2194

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-020320 · form4.xml · nonDerivative · entry 5

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,937.2194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-22-020320 · form4.xml · nonDerivative · entry 4

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,887.2194

SEC source: 0001127602-22-020320 · form4.xml · nonDerivative · entry 3

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,897.2194

SEC source: 0001127602-22-020320 · form4.xml · nonDerivative · entry 2

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,654.2194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-020320 · form4.xml · nonDerivative · entry 1

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,887.2194

SEC source: 0001127602-25-005895 · form4.xml · nonDerivative · entry 1

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,993.2194

F1 · kind: Represents a charitable donation to a donor advised fund.

SEC source: 0001127602-22-017356 · form4.xml · nonDerivative · entry 1

Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,171.9166

SEC source: 0001127602-22-010699 · form4.xml · nonDerivative · entry 1

Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,605.4989

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001127602-22-010698 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,287.018

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

SEC source: 0001127602-22-010501 · form4.xml · nonDerivative · entry 2

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,736.018

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-010506 · form4.xml · nonDerivative · entry 2

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,502

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-010505 · form4.xml · nonDerivative · entry 2

Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,129.9106

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-010503 · form4.xml · nonDerivative · entry 2

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,915

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-010504 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,158

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-010502 · form4.xml · nonDerivative · entry 2

Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,961.4989

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-010500 · form4.xml · nonDerivative · entry 2

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,696.2194

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-22-010501 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,528.018

F1 · kind: Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021.

SEC source: 0001127602-22-010506 · form4.xml · nonDerivative · entry 1

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,862

F1 · kind: Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021.

SEC source: 0001127602-22-010505 · form4.xml · nonDerivative · entry 1

Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,012.9106

F1 · kind: Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021.

SEC source: 0001127602-22-010503 · form4.xml · nonDerivative · entry 1

Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,563

F1 · kind: Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021.

SEC source: 0001127602-22-010504 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,444

F1 · kind: Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021.